Predicted protein targets (top 6)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NT5E | P21589 | 18/20 | 0.44 |
| ▸ | ADORA3 | P0DMS8 | 1/20 | 0.40 |
| ▸ | ADORA2A | P29274 | 1/20 | 0.40 |
| ▸ | ADORA1 | P30542 | 1/20 | 0.40 |
| ▸ | PRMT5 | O14744 | 1/20 | 0.39 |
| ▸ | WDR77 | Q9BQA1 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL21839763 | 0.81 | NT5E (0.62) | NT5E | |
| SCHEMBL23914880 | 0.81 | NT5E (0.62) | NT5E | |
| SCHEMBL21839525 | 0.81 | NT5E (0.62) | NT5E | |
| SCHEMBL23915788 | 0.81 | NT5E (0.62) | NT5E | |
| SCHEMBL23907591 | 0.80 | NT5E (0.49) | NT5EADORA3ADORA2AADORA1 | |
| SCHEMBL23907442 | 0.80 | ADORA3 (0.50) | NT5EADORA3ADORA2AADORA1 | |
| SCHEMBL30394929 | 0.79 | NT5E (0.57) | NT5EPRMT5WDR77 | |
| SCHEMBL23907419 | 0.79 | NT5E (0.46) | NT5EADORA3ADORA2AADORA1 | |
| SCHEMBL30394904 | 0.79 | NT5E (0.57) | NT5EPRMT5WDR77 | |
| SCHEMBL30395313 | 0.79 | NT5E (0.41) | NT5EADORA3ADORA2AADORA1PRMT5 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11591355-B2 | CD73 inhibitors and uses thereof | PELOTON THERAPEUTICS INC. (US) | 2023-02-28 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11591355-B2 | CD73 inhibitors and uses thereof | ENTPD5, ENTPD1, ENTPD3 | NT5E 5/4885ADORA3 9/4885ADORA2A 8/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.